PSNCBAM-1, a novel allosteric antagonist at cannabinoid CB(1) receptors with hypophagic effects in rats

BACKGROUND AND PURPOSE: Rimonabant (Acomplia(TM), SR141716A), a cannabinoid CB(1) receptor inverse agonist, has recently been approved for the treatment of obesity. There are, however, concerns regarding its side effect profile. Developing a CB(1) antagonist with a different pharmacological mechanis...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Horswill, J G, Bali, U, Shaaban, S, Keily, J F, Jeevaratnam, P, Babbs, A J, Reynet, C, Wong Kai In, P
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2007
Assuntos:
Research Papers
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2190018/
https://ncbi.nlm.nih.gov/pubmed/17592509
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjp.0707347
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados